Canopy Growth (NASDAQ:CGC) and MTL Cannabis announced the successful closing of their previously disclosed arrangement on Monday.
Under the terms of the agreement, Canopy Growth has acquired 100% of the issued and outstanding common shares of MTL, integrating one of Canada's most respected premium flower producers into its global operations.
The merger creates what the companies describe as Canada’s leading medical cannabis platform.
By bringing MTL’s high-quality cultivation expertise in-house, Canopy Growth expects to significantly enhance its ability to meet the rising demand for premium products in both the domestic adult-use market and regulated international medical markets, specifically in Europe.
The transaction is a centerpiece of Canopy's broader strategy to transition into a "brand-light" asset model that prioritizes top-tier product quality and operational efficiency.
Financially, the integration of MTL—a business noted for being profitable and cash-generating—is expected to provide an immediate boost to Canopy’s balance sheet.
Management reaffirmed that this acquisition is a key driver in achieving the company's stated goal of reaching positive adjusted EBITDA during fiscal 2027.
The move follows a multi-year period of restructuring and divestment for Canopy as it sought to right-size its Canadian footprint.